Prediction of individual responce to platinum/paclitaxel combination using novel marker genes in ovarian cancers

Molecular Cancer Therapeutics

Volumn 5, Issue 3, 2006, Pages 767-775

  Komatsu, Masaaki ^a,b   Hiyama, Keiko ^a   Tanimoto, Keiji ^a   Yunokawa, Mayu ^a,b   Otani, Keiko ^a   Ohtaki, Megu ^a   Hiyama, Eiso ^b   Kigawa, Junzo ^c   Ohwada, Michitaka ^d   Suzuki, Mitsuaki ^d   Nagai, Nobutaka ^b   Kudo, Yoshiki ^b   Nishiyama, Masahiko ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c National Hospital Organization   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; PLATINUM; TUMOR MARKER;

ACCURACY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOINFORMATICS; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA MICROARRAY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC CORRELATION; GENETIC MARKER; GYNECOLOGIC SURGERY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IC 50; IN VITRO STUDY; MULTIPLE REGRESSION; NUCLEOTIDE SEQUENCE; OVARY CANCER; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; BIOLOGICAL MODEL; DRUG RESISTANCE; GENETICS; OVARY TUMOR; PROGNOSIS; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR GENE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, NEOPLASM; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, BIOLOGICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33645471979     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0408     Document Type: Article

References (42)

1. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science 2000;287:1969-73.
2. Nishiyama M. Cancer pharmacogenomics: progress and obstacles toward the goal. Int J Clin Oncol 2005;10:3-4.
3. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91.
4. Marsh S, McLeod HL. Cancer pharmacogenetics. Br J Cancer 2004;90: 8-11.
5. Tanaka T, Tanimoto K, Otani K, et al. Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer 2004;111:617-26.
6. Ozols RF. Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer. Cancer Invest 2004;22(Suppl 2):11-20.
7. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
8. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200.
9. Hartmann LC, Lu KH, Linette GP, et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 2005;11:2149-55.
10. Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005;11:3686-96.
11. Staunton JE, Slonim DK, Coller HA, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 2001; 98:10787-92.
12. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001; 41:101-21.
13. Ohtaki M, Otani K, Satoh K, Kawamura T, Hiyama K, Nishiyama M. Model-based analysis of microarray data: exploration of differentially expressed genes between two cell types based on a two-dimensional mixed normal model. Jpn J Biomet 2005;26:31-48.
14. Hiyama K, Otani K, Ohtaki M, et al. Differentially expressed genes throughout the cellular immortalization processes are quite different between normal human fibroblasts and endothelial cells. Int J Oncol 2005;27:87-95.
15. Rousseeuw PJ. Least median of squares regression. J Am Stat Assoc 1984;79:871-80.
16. Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 2005;107:155-76.
17. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human carcinoma cell lines. Cancer Res 1995; 55:4633-9.
18. Murata T, Haisa M, Uetsuka H, et al. Molecular mechanism of chemoresistance to cisplatin in ovarian cancer cell lines. Int J Mol Med 2004;13:865-8.
19. Manenti L, Riccardi E, Marchini S, et al. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther 2005;4:715-25.
20. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22:2594-601.
21. Duan Z, Brakora KA, Seiden MV. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 2004;3:833-8.
22. Taniguchi R, Kumai T, Matsumoto N, et al. Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4. J Pharmacol Sci 2005;97:83-90.
23. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988;241:1813-5.
24. Hengstler JG, Lange J, Kett A, et al. Contribution of c-erbB-2 and topoisomerase IIα to chemoresistance in ovarian cancer. Cancer Res 1999;59:3206-14.
25. Bani MR, Nicoletti MI, Alkharouf NW, et al. Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther 2004;3:111-21.
26. Huang J, Mohanty S, Basu A. Cisplatin resistance is associated with deregulation in protein kinase C-δ. Biochem Biophys Res Commun 2004; 316:1002-8.
27. Papouli E, Cejka P, Jiricny J. Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res 2004;64:3391-4.
28. Xu ZY, Loignon M, Han FY, Panasci L, Aloys R. Xrcc3 induces cisplatin resistance by stimulation of rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther 2005;314:495-505.
29. Novak AJ, Grote DM, Stenson M, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004;104:2247-53.
30. de Veer MJ, Sim H, Whisstock JC, Devenish RJ, Ralph SJ. IFI60/ISG60/IFIT4, a new member of the human IFI54/IFIT2 family of interferon-stimulated genes. Genomics 1998;54:267-77.
31. Rhodes DA, Stammers M, Malcherek G, Beck S, Trowsdale J. The cluster of BTN genes in the extended major histocompatibility complex. Genomics 2001;71:351-62.
32. Rodriguez OC, Cheney RE. Human myosin-Vc is a novel class V myosin expressed in epithelial cells. J Cell Sci 2002;115:991-1004.
33. Le Marechal C, Chen JM, Le Gall C, et al. Two novel severe mutations in the pancreatic secretory trypsin inhibitor gene (SPINK1) cause familial and/or hereditary pancreatitis. Hum Mutat 2004;23:205.
34. Weiss FU, Simon P, Witt H, et al. SPINK1 mutations and phenotypic expression in patients with pancreatitis associated with trypsinogen mutations. J Med Genet 2003;40:e40.
35. Kurochkin IV, Yonemitsu N, Funahashi SI, Nomura H. ALEX1, a novel human armadillo repeat protein that is expressed differentially in normal tissues and carcinomas. Biochem Biophys Res Commun 2001;280:340-7.
36. Inazu T, Yamada K, Miyamoto K. Cloning and expression of pleckstrin 2, a novel member of the pleckstrin family. Biochem Biophys Res Commun 1999;265:87-93.
37. Hu MH, Bauman EM, Roll RL, Yeilding N, Abrams CS. Pleckstrin 2, a widely expressed paralog of pleckstrin involved in actin rearrangement. J Biol Chem 1999;274:21515-8.
38. Sayer RA, Lancaster JM, Pittman J, et al. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol 2005;96:355-61.
39. Baldi A, De Luca A, Morini M, et al. The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene 2002;21:6684-8.
40. Chien J, Staub J, Hu SI, et al. A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene 2004;23:1636-44.
41. Berchuck A, Lancaster JM, Iversen ES, et al. Molecular profiling of patients with ovarian cancer and the potential for individualized therapy. In: Perry MC, editor. American Society of Clinical Oncology Educational Book 2005. Alexandria: American Society of Clinical Oncology; 2005. p. 416-20.
42. Taylor AE, Wiltshaw E, Gore ME, et al. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 1994;12:2066-70.